Quick Answer
Royalty Pharma plc reported Total Revenue of $2.38 billion for fiscal year 2025.
Royalty Pharma plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.38B +5.1% |
$2.26B -3.9% |
$2.35B +5.2% |
$2.24B -2.3% |
$2.29B +7.9% |
$2.12B +17.0% |
| Net Income | $770.95M -10.2% |
$858.98M -24.3% |
$1.13B +2549.5% |
$42.83M -93.1% |
$619.73M -36.4% |
$975.04M -58.5% |
| Diluted EPS | $1.78 -6.8% |
$1.91 -24.5% |
$2.53 +2430.0% |
$0.10 -93.3% |
$1.49 +12.9% |
$1.32 |
| Total Assets | $19.62B +7.7% |
$18.22B +11.2% |
$16.38B -2.6% |
$16.81B -4.0% |
$17.52B +9.3% |
$16.02B +28.7% |
| Cash and Equivalents | $618.70M -33.4% |
$929.03M +94.8% |
$477.01M -72.1% |
$1.71B +11.0% |
$1.54B +52.8% |
$1.01B +309.7% |
| Long-Term Debt | $8.57B +29.6% |
$6.61B +7.8% |
$6.14B +0.3% |
$6.12B -13.8% |
$7.10B +22.0% |
$5.82B -2.3% |
| Stockholders Equity | $9.71B -6.1% |
$10.34B +2.6% |
$10.08B +5.9% |
$9.53B -7.1% |
$10.25B +3.6% |
$9.90B +61.1% |
| R&D Expense | $452.00M +22500.0% |
$2.00M -96.2% |
$52.00M -70.6% |
$177.11M -11.5% |
$200.08M +661.1% |
$26.29M -68.3% |
| Operating Income | $1.56B +20.7% |
$1.29B -13.4% |
$1.49B +385.9% |
$307.06M -78.5% |
$1.43B -10.3% |
$1.60B -39.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $609.29M | +7.9% | +5.3% |
| Net Income | September 30, 2025 | $288.22M | -47.0% | +855.1% |
| Diluted EPS | September 30, 2025 | $0.67 | -44.6% | +857.1% |
| Total Assets | September 30, 2025 | $19.35B | +7.2% | +5.6% |
| Cash and Equivalents | September 30, 2025 | $938.94M | -1.2% | +48.6% |
| Long-Term Debt | September 30, 2025 | $8.57B | +29.6% | +22.3% |
| Stockholders Equity | September 30, 2025 | $9.62B | -6.2% | +1.2% |
| R&D Expense | September 30, 2025 | $50.50M | +10000.0% | -83.2% |
| Operating Income | September 30, 2025 | $427.16M | -41.9% | +103.6% |
- Royalty Pharma plc reported Total Revenue of $2.38 billion for fiscal year 2025.
- Royalty Pharma plc showed an increase of +5.1% in Total Revenue compared to the prior fiscal year.
- Royalty Pharma plc reported Net Income of $770.95 million for fiscal year 2025.
- Royalty Pharma plc showed a decrease of -10.2% in Net Income compared to the prior fiscal year.
- Royalty Pharma plc reported Diluted EPS of $1.78 per share for fiscal year 2025.
- Royalty Pharma plc showed a decrease of -6.8% in Diluted EPS compared to the prior fiscal year.
- Royalty Pharma plc reported Total Assets of $19.62 billion for fiscal year 2025.
- Royalty Pharma plc showed an increase of +7.7% in Total Assets compared to the prior fiscal year.
- Royalty Pharma plc reported Cash and Equivalents of $618.70 million for fiscal year 2025.
- Royalty Pharma plc showed a decrease of -33.4% in Cash and Equivalents compared to the prior fiscal year.
- Royalty Pharma plc reported Long-Term Debt of $8.57 billion for fiscal year 2025.
- Royalty Pharma plc showed an increase of +29.6% in Long-Term Debt compared to the prior fiscal year.
- Royalty Pharma plc reported Stockholders Equity of $9.71 billion for fiscal year 2025.
- Royalty Pharma plc showed a decrease of -6.1% in Stockholders Equity compared to the prior fiscal year.
- Royalty Pharma plc reported R&D Expense of $452.00 million for fiscal year 2025.
- Royalty Pharma plc showed an increase of +22500.0% in R&D Expense compared to the prior fiscal year.
- Royalty Pharma plc reported Operating Income of $1.56 billion for fiscal year 2025.
- Royalty Pharma plc showed an increase of +20.7% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: